GALAPAGOS GENOMICS WKN: A0EAT9 ISIN: BE0003818359 Kürzel: GLPG Forum: Aktien Thema: Hauptdiskussion

Galapagos GAAP EPS of €0.43, revenue of €328.8M https://seekingalpha.com/news/3997161-galapagos-gaap-eps-of-043-revenue-of-3288m • Galapagos press release (NASDAQ:GLPG): 1H GAAP EPS of €0.43. • Revenue of €328.8M (+20.0% Y/Y).

Galapagos announces first half-year 2023 financial results https://www.glpg.com/press-release/3874/galapagos-announces-first-half-year-2023-financial-results

Galapagos GAAP EPS of €0.40, revenue of €178.9M https://seekingalpha.com/news/3965935-galapagos-gaap-eps-of-040-revenue-of-1789m • Galapagos press release (NASDAQ:GLPG): Q1 GAAP EPS of €0.40. • Revenue of €178.9M (+31.3% Y/Y). • Current financial investments and cash and cash equivalents totaled €3,990.1 million on 31 March 2023, as compared to €4,094.1 million on 31 December 2022. • We reiterate our full year 2023 cash burn guidance in the range of €380 and €420 million.

https://www.finanznachrichten.de/nachrichten-2023-05/58975776-galapagos-nv-galapagos-announces-departure-of-bart-filius-chief-operating-officer-and-chief-financial-officer-399.htm

diese Bewertung ist doch nur noch verrückt ... MK 2 ...Cash 4 Mrd. ..dazu die ganze Pipeline incl.Med was schon FCF generiert .. Verrückt Verrückter Galapagos

Galapagos to transfer drug discovery and research activities in France to NovAliX https://seekingalpha.com/news/3952944-galapagos-to-transfer-drug-discovery-and-research-activities-in-france-to-novalix • Belgian biotech Galapagos NV (NASDAQ:GLPG) on Thursday said it would transfer its drug discovery and research activities in Romainville, France to contract research organization NovAliX. • NovAliX will assume GLPG's research capabilities while GLPG will retain flexibility to access "necessary expertise and resources" through a five year-collaboration agreement, the company said in a statement. • The move by GLPG comes as part of its strategic reset announced in 2022. The deal is expected to close in July this year. • GLPG's employees in Romainville will also be transferred to NovAliX • The company said the financial impact of the deal is included in its previously announced 2023 cash burn guidance in the range of €380M to €420M.

https://www.glpg.com/press-release/3812/galapagos-and-novalix-enter-into-an-integrated-drug-discovery-collaboration

Oder ?

Also bekommst du das Unternehmen geschenkt … Das ist doch verrückt 😜

Roundabout 4 mrd.

Wieviel Nettocash haben sie noch ?

Galapagos reports FY 2022 results, sees further reduction of cash burn in FY 2023 https://seekingalpha.com/news/3940356-galapagos-reports-fy-2022-results-sees-further-reduction-of-cash-burn-in-fy-2023 • Galapagos press release (NASDAQ:GLPG): FY GAAP EPS of -€3.32 misses by €2.21. • Revenue of €505.3M (+4.2% Y/Y) misses by €77M. • For FY 2023, co anticipates further reduction of its cash burn and anticipates landing between €380 and €420 million (compared to €514 million for FY 2022). • Anticipates between €140 and €160 million net sales of Jyseleca for FY 2023.

Galapagos announces full year 2022 results and outlook for 2023 https://www.globenewswire.com/news-release/2023/02/23/2614774/0/en/Galapagos-announces-full-year-2022-results-and-outlook-for-2023.html

Jefferies Upgrades Galapagos to Hold, Lowers Price Target to $47.2 https://www.benzinga.com/news/23/01/30518170/jefferies-upgrades-galapagos-to-hold-lowers-price-target-to-47-2 Jefferies analyst Peter Welford upgrades Galapagos (NASDAQ:GLPG) from Underperform to Hold and lowers the price target from $49 to $47.2.

https://finance.yahoo.com/news/galapagos-announces-changes-executive-committee-210100169.html

Belgian biotech company Galapagos on the hunt for deals https://www.ft.com/content/06c089ca-8810-493d-ab40-c3fa02ff8779 Former Johnson & Johnson executive ‘on the look out’ for rivals amid biotech sell-off The former chief scientific officer of Johnson & Johnson is on the hunt for acquisitions after he took the reins at the struggling Belgian biotech Galapagos this year. Paul Stoffels is on a “mission” to reinstate Galapagos as a top European biotech player. He has returned to lead the company he co-founded in 1999, attracted to its strong balance sheet of €4.4bn in cash and current financial investments, and he is seeking to spread access to innovative cancer treatments in Europe. Stoffels said he was on the “look out” for companies with good drugs that had not yet reached human trials or were in the early stages that Galapagos could accelerate to market. After the worst biotech sell-off since the early 2000s, he said valuations were starting to appear attractive. ... But in a biotech downturn, he must convince investors that the company, with a market capitalisation of €2.5bn, should be valued at more than the cash on its balance sheet. He said he would like to see the market capitalisation above the cash balance next year. ...